Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 786 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... October 6, 2022 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 Urine test for bladder cancer being developed July 2, 2021 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Load more HOT NEWS A tribute to Professor Gordon McVie Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer 癌症治疗期间如何保证日常活动的安全和独立执行 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion
